FDA Approves ‘Thrombotech’ Phase IIa Trial For Stroke Treatment
Israeli biotechnology company Thrombotech has obtained US Food and Drug Administration (FDA) approval for a Phase IIa clinical trial of its treatment for ischemic stroke by destroying blood clots. The trial will be conducted in the US and will test the safety of the drug, THR-18. The clinical trial was initiated at Hadassah Medical Center […]
February 29, 2012